HomeCompareSPOFF vs ABBV

SPOFF vs ABBV: Dividend Comparison 2026

SPOFF yields 853.24% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPOFF wins by $4793389.11M in total portfolio value
10 years
SPOFF
SPOFF
● Live price
853.24%
Share price
$0.23
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4793389.21M
Annual income
$3,895,322,146,072.43
Full SPOFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SPOFF vs ABBV

📍 SPOFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPOFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPOFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPOFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPOFF
Annual income on $10K today (after 15% tax)
$72,525.60/yr
After 10yr DRIP, annual income (after tax)
$3,311,023,824,161.57/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SPOFF beats the other by $3,311,023,803,105.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPOFF + ABBV for your $10,000?

SPOFF: 50%ABBV: 50%
100% ABBV50/50100% SPOFF
Portfolio after 10yr
$2396694.66M
Annual income
$1,947,661,085,422.09/yr
Blended yield
81.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SPOFF
No analyst data
Altman Z
5.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPOFF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPOFFABBV
Forward yield853.24%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4793389.21M$102.3K
Annual income after 10y$3,895,322,146,072.43$24,771.77
Total dividends collected$4723116.64M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPOFF vs ABBV ($10,000, DRIP)

YearSPOFF PortfolioSPOFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$96,024$85,324.23$11,550$430.00+$84.5KSPOFF
2$868,465$765,719.05$13,472$627.96+$855.0KSPOFF
3$7,401,535$6,472,277.72$15,906$926.08+$7.39MSPOFF
4$59,471,328$51,551,685.23$19,071$1,382.55+$59.45MSPOFF
5$450,753,701$387,119,380.04$23,302$2,095.81+$450.73MSPOFF
6$3,224,466,521$2,742,160,060.72$29,150$3,237.93+$3224.44MSPOFF
7$21,782,928,256$18,332,749,078.83$37,536$5,121.41+$21782.89MSPOFF
8$139,052,724,266$115,744,991,031.68$50,079$8,338.38+$139052.67MSPOFF
9$839,315,011,698$690,528,596,733.33$69,753$14,065.80+$839314.94MSPOFF
10$4,793,389,208,589$3,895,322,146,072.43$102,337$24,771.77+$4793389.11MSPOFF

SPOFF vs ABBV: Complete Analysis 2026

SPOFFStock

EarthLabs Inc. operates as a technology services company in mineral exploration in Canada. The company operates in two segments, Exploration Technology Division and Financial Technology Division. The Exploration Technology Division segment offers LithoLens, a proprietary core imaging technology that automatically and consistently examines old core images to create fresh and accurate geological logs; MinusOne, a proprietary geophysical data inversion platform for creating 3-D models from geophysical data processed using deterministic and stochastic inversion methods; GeoFEZ, a processing software that extracts new insight from common exploration data, such as potential field data, topographic data, hyperspectral data, radiometric data, and electromagnetic data; and multi-parameter acquisition survey system, which allows the simultaneous capture of gradient magnetics, LiDAR, 4-band orthophoto imagery, and electromagnetic information in the very low frequency band and radiometric data. This segment also provides GeoticLog, a customizable core-logging platform; GeoticMine, a 3-D geological modelling and visualization solution; GeoticSection, a drill-hole visualizer; GeoticCAD, an industry tool with an integrated drawing motor; and GeoticField, a field-based survey data entry platform. The Financial Technology Division segment offers Resource Quantamental, an artificial intelligence decision engine for investments; CEO.CA, a social network for investors and traders in junior resource and venture stocks with online and mobile functionality; and DigiGeoAtlas platform, a software-based GIS interactive mapping interface alongside its DigiGeoMaps distribution business, as well as provides a range of cloud-based and interoperable web applications. This segment also provides smart targets, image analytics, geophysics, structural geology, geochemistry, and field geology services. The company was formerly known as GoldSpot Discoveries Corp. and changed its name to EarthLabs Inc. in September 2022. EarthLabs Inc. is headquartered in Toronto, Canada.

Full SPOFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SPOFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPOFF vs SCHDSPOFF vs JEPISPOFF vs OSPOFF vs KOSPOFF vs MAINSPOFF vs JNJSPOFF vs MRKSPOFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.